Moderna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial
Economic Times 1 hr ago·19 Aug 2026, 2:26 pm
Moderna’s stock price jumped sharply after the company announced positive results from a late-stage clinical trial for its personalized mRNA cancer vaccine. The treatment, used alongside the drug Keytruda, demonstrated a significant reduction in the risk of recurrence and spread for patients with melanoma. This marks a major milestone for the company, as it is the first time an mRNA cancer vaccine has shown success in such advanced trials.
For investors, the news is a significant development for Moderna’s long-term growth strategy. It signals a potential shift in the company’s business model beyond its COVID-19 vaccines and opens the door to a massive new market. The focus now shifts to regulatory discussions and how the company plans to scale this technology for broader use.
Investors should monitor the upcoming discussions with regulators and the timeline for potential approval. The success of this trial validates the broader potential of mRNA technology, but the stock’s future performance will depend on execution and the broader adoption of the therapy.
Key takeaways
- Category: Economy.
- AI reads the tone as positive (potentially bullish) for the stock.
- Flagged as a high-impact, market-moving story.
Why it matters
This is a high-impact development and could move the stock. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
